$10.90
0[0.00%]
At close: Apr 24
$10.90
0[0.00%]
PreMarket: 4:03PM EDT
Roivant Sciences
(NASDAQ:ROIV)Roivant Sciences Stock (NASDAQ:ROIV), Analyst Ratings, Price Targets, Predictions
Roivant Sciences Ltd has a consensus price target of $14.27, established from looking at the 51 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Goldman Sachs, and HC Wainwright & Co. on April 22, 2024, April 3, 2024, and April 3, 2024. With an average price target of $18 between HC Wainwright & Co., Goldman Sachs, and HC Wainwright & Co., there's an implied 65.14% upside for Roivant Sciences Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Goldman Sachs
Deutsche Bank
Truist Securities
Wolfe Research
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Roivant Sciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/22/2024 | ROIV | Buy Now | Roivant Sciences | $10.90 | 65.14% | HC Wainwright & Co. | Douglas Tsao | → $18 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | ROIV | Buy Now | Roivant Sciences | $10.90 | 65.14% | Goldman Sachs | Corinne Jenkins | $16 → $18 | Maintains | Buy | Get Alert |
| 04/03/2024 | ROIV | Buy Now | Roivant Sciences | $10.90 | 65.14% | HC Wainwright & Co. | Douglas Tsao | $17 → $18 | Maintains | Buy | Get Alert |
| 04/03/2024 | ROIV | Buy Now | Roivant Sciences | $10.90 | 37.61% | Deutsche Bank | Neena Bitritto-Garg | $14 → $15 | Maintains | Buy | Get Alert |
| 03/25/2024 | ROIV | Buy Now | Roivant Sciences | $10.90 | 111.01% | Truist Securities | Robyn Karnauskas | → $23 | Reiterates | Buy → Buy | Get Alert |
| 02/15/2024 | ROIV | Buy Now | Roivant Sciences | $10.90 | 55.96% | Wolfe Research | Andy Chen | → $17 | Initiates | → Outperform | Get Alert |
| 02/14/2024 | ROIV | Buy Now | Roivant Sciences | $10.90 | 55.96% | HC Wainwright & Co. | Douglas Tsao | $18 → $17 | Maintains | Buy | Get Alert |
| 01/05/2024 | ROIV | Buy Now | Roivant Sciences | $10.90 | 83.49% | Piper Sandler | Allison Bratzel | → $20 | Initiates | → Overweight | Get Alert |
| 01/02/2024 | ROIV | Buy Now | Roivant Sciences | $10.90 | 10.09% | B of A Securities | Chi Fong | $11 → $12 | Maintains | Neutral | Get Alert |
| 12/12/2023 | ROIV | Buy Now | Roivant Sciences | $10.90 | 28.44% | Deutsche Bank | Neena Bitritto-Garg | → $14 | Initiates | → Buy | Get Alert |
| 11/15/2023 | ROIV | Buy Now | Roivant Sciences | $10.90 | 46.79% | Guggenheim | Yatin Suneja | $17 → $16 | Maintains | Buy | Get Alert |
| 11/14/2023 | ROIV | Buy Now | Roivant Sciences | $10.90 | 37.61% | JP Morgan | Brian Cheng | $16 → $15 | Maintains | Overweight | Get Alert |
| 10/17/2023 | ROIV | Buy Now | Roivant Sciences | $10.90 | 55.96% | Guggenheim | Yatin Suneja | → $17 | Initiates | → Buy | Get Alert |
| 09/27/2023 | ROIV | Buy Now | Roivant Sciences | $10.90 | 46.79% | Goldman Sachs | Corinne Jenkins | $14 → $16 | Maintains | Buy | Get Alert |
| 09/26/2023 | ROIV | Buy Now | Roivant Sciences | $10.90 | 111.01% | Truist Securities | Robyn Karnauskas | → $23 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2023 | ROIV | Buy Now | Roivant Sciences | $10.90 | 37.61% | Cantor Fitzgerald | Louise Chen | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 09/05/2023 | ROIV | Buy Now | Roivant Sciences | $10.90 | 37.61% | Cantor Fitzgerald | Louise Chen | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 08/31/2023 | ROIV | Buy Now | Roivant Sciences | $10.90 | 37.61% | Cantor Fitzgerald | Louise Chen | → $15 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | ROIV | Buy Now | Roivant Sciences | $10.90 | 37.61% | Cantor Fitzgerald | Louise Chen | → $15 | Reiterates | Overweight → Overweight | Get Alert |
FAQ
What is the target price for Roivant Sciences (ROIV)?
The latest price target for Roivant Sciences (NASDAQ: ROIV) was reported by HC Wainwright & Co. on April 22, 2024. The analyst firm set a price target for $18.00 expecting ROIV to rise to within 12 months (a possible 65.14% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Roivant Sciences (ROIV)?
The latest analyst rating for Roivant Sciences (NASDAQ: ROIV) was provided by HC Wainwright & Co., and Roivant Sciences reiterated their buy rating.
When was the last upgrade for Roivant Sciences (ROIV)?
There is no last upgrade for Roivant Sciences.
When was the last downgrade for Roivant Sciences (ROIV)?
There is no last downgrade for Roivant Sciences.
When is the next analyst rating going to be posted or updated for Roivant Sciences (ROIV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Roivant Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Roivant Sciences was filed on April 22, 2024 so you should expect the next rating to be made available sometime around April 22, 2025.
Is the Analyst Rating Roivant Sciences (ROIV) correct?
While ratings are subjective and will change, the latest Roivant Sciences (ROIV) rating was a reiterated with a price target of $0.00 to $18.00. The current price Roivant Sciences (ROIV) is trading at is $10.90, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.